ATE307598T1 - Verwendung eines zyklischen ethers zur herstellung von mitteln, die die glukosetoleranz beeinflussen - Google Patents

Verwendung eines zyklischen ethers zur herstellung von mitteln, die die glukosetoleranz beeinflussen

Info

Publication number
ATE307598T1
ATE307598T1 AT01901338T AT01901338T ATE307598T1 AT E307598 T1 ATE307598 T1 AT E307598T1 AT 01901338 T AT01901338 T AT 01901338T AT 01901338 T AT01901338 T AT 01901338T AT E307598 T1 ATE307598 T1 AT E307598T1
Authority
AT
Austria
Prior art keywords
glucose tolerance
cyclic ether
agents
production
affect glucose
Prior art date
Application number
AT01901338T
Other languages
English (en)
Inventor
Bo Ahren
Shukun Yu
Original Assignee
Danisco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco filed Critical Danisco
Application granted granted Critical
Publication of ATE307598T1 publication Critical patent/ATE307598T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT01901338T 2000-01-14 2001-01-12 Verwendung eines zyklischen ethers zur herstellung von mitteln, die die glukosetoleranz beeinflussen ATE307598T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0000888A GB2358137B (en) 2000-01-14 2000-01-14 Compound
PCT/IB2001/000139 WO2001051058A1 (en) 2000-01-14 2001-01-12 Use of a cyclic ether for the preparation of medicaments affecting glucose tolerance

Publications (1)

Publication Number Publication Date
ATE307598T1 true ATE307598T1 (de) 2005-11-15

Family

ID=9883727

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01901338T ATE307598T1 (de) 2000-01-14 2001-01-12 Verwendung eines zyklischen ethers zur herstellung von mitteln, die die glukosetoleranz beeinflussen

Country Status (12)

Country Link
US (1) US20020198158A1 (de)
EP (1) EP1246626B1 (de)
JP (1) JP2003519660A (de)
KR (1) KR100804622B1 (de)
CN (1) CN1208066C (de)
AT (1) ATE307598T1 (de)
AU (1) AU783221B2 (de)
BR (1) BR0107160A (de)
CA (1) CA2383158A1 (de)
DE (1) DE60114362T2 (de)
GB (1) GB2358137B (de)
WO (1) WO2001051058A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1466422A (zh) * 2000-09-27 2004-01-07 丹尼斯科有限公司 抗微生物剂
WO2003037906A1 (en) * 2001-10-31 2003-05-08 Danisco A/S Antimicrobial use of anhydrofructose derivatives
IL152397A (en) 2002-10-21 2009-02-11 Hadasit Med Res Service Compositions and compounds for the treatment of hyperglycemia
EP1686122B1 (de) * 2003-10-28 2012-11-21 Nihon Starch Co., Ltd. Antitumorales mittel
WO2005121114A2 (en) * 2004-06-07 2005-12-22 Glycom Aps 1,5 and 1,4-anhydroketoses, methods for the preparation of 1,5-and 1,4-anhydroketoses, intermediates, and uses of 1,5-and 1,4-anhydroketoses
JP4825957B2 (ja) * 2005-03-29 2011-11-30 国立大学法人 鹿児島大学 抗腫瘍剤
JP5229854B2 (ja) * 2007-02-09 2013-07-03 日本澱粉工業株式会社 動脈硬化症の予防または改善剤
JP5637865B2 (ja) * 2009-01-19 2014-12-10 国立大学法人富山大学 １，５−ａｇ含有組成物
JP2012001515A (ja) * 2010-06-21 2012-01-05 Toyama Univ グリコーゲン分解酵素阻害剤
WO2016171165A1 (ja) * 2015-04-21 2016-10-27 国立大学法人鹿児島大学 カスパーゼ１活性化阻害剤
JP7185226B2 (ja) * 2018-11-22 2022-12-07 国立大学法人 鹿児島大学 １，５－アンヒドロフルクトース誘導体を含むａｍｐｋ活性化剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6279780A (ja) * 1985-05-28 1987-04-13 Nippon Kayaku Co Ltd １，５―アンヒドログルシトールの定量法
JPH0665080A (ja) * 1992-03-10 1994-03-08 Godo Shiyusei Kk α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食

Also Published As

Publication number Publication date
KR100804622B1 (ko) 2008-02-20
GB0000888D0 (en) 2000-03-08
DE60114362T2 (de) 2006-07-06
EP1246626A1 (de) 2002-10-09
DE60114362D1 (de) 2005-12-01
CA2383158A1 (en) 2001-07-19
AU2700501A (en) 2001-07-24
CN1394142A (zh) 2003-01-29
BR0107160A (pt) 2002-06-18
AU783221B2 (en) 2005-10-06
KR20020032616A (ko) 2002-05-03
EP1246626B1 (de) 2005-10-26
US20020198158A1 (en) 2002-12-26
JP2003519660A (ja) 2003-06-24
CN1208066C (zh) 2005-06-29
GB2358137B (en) 2004-06-09
GB2358137A (en) 2001-07-18
WO2001051058A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
NI200500164A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas, correspondiente metodo de produccion, medicamentos que contienen dicho compuesto y su uso.
YU91002A (sh) Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
DE502006005523D1 (de) Pentafluorsulfanyl-substituierte verbindung und deren verwendung zur herstellung von arzneimitteln
BR0010768A (pt) Processo de preparação de "alfa"-metilenolactonas
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
ATE307598T1 (de) Verwendung eines zyklischen ethers zur herstellung von mitteln, die die glukosetoleranz beeinflussen
UA99657C2 (ru) Фильтр для курительного изделия, курительное изделие и способ его изготовления
CY1110541T1 (el) Φαρμακευτικα σκευασματα με βελτιωμενες φαρμακευτικες ιδιοτητες που περιεχουν βελτιωτικα γευσης
PT1210384E (pt) Composicoes de revestimento inorganicas, um processo para a sua preparacao bem como a sua utilizacao
ATE461934T1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-car onsäure -lacton und schlüsselzwischenprodukte für dieses verfahren
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
DE502005011199D1 (de) Herstellung eines von willenbrand faktor-präparates mit hoher spezifischer aktivität
TW200720241A (en) New process for preparing 4,4'-difluorobenzophenone
BG104034A (en) Method for the preparation of pharmaceutical compounds of antidepressive effect and against the parkinson syndrome effect
SE9904121D0 (sv) Hydrophobe biomolecular structure
ATE462687T1 (de) Verfahren zur herstellung von azoverbindungen
TW200716656A (en) Processes for the preparation of paclitaxel
DE60103560D1 (de) Prozess zur herstellung von paclitaxel
MXPA04000712A (es) METODOS PARA PROMOCION DE CRECIMIENTO DE CABELLO QUE COMPRENDEN APLICACION TOPICA DE ANaLOGOS DE PROSTAGLANDINA.
DE60236303D1 (de) Verfahren zur herstellung von 14-beta-hydroxybaccatin-iii-1,14-carbonat
ATE537160T1 (de) Verfahren zur herstellung von 14beta- hydroxybaccatin-iii-1,14-carbonat
SE0400522D0 (sv) A medical solution, a method for producing said medical solution and use thereof
MXPA03003466A (es) Derivados de piranosido.
ATE274909T1 (de) Verwendung von alprostadil (prostaglandin e1) zur herstellung eines arzneimittels für angioneogenese

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties